These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35802024)

  • 21. IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective.
    Tarantini F; Cumbo C; Parciante E; Anelli L; Zagaria A; Coccaro N; Minervini CF; Tota G; Redavid I; Conserva MR; Attolico I; Rossi AR; Specchia G; Musto P; Albano F
    Acta Haematol; 2023; 146(1):37-43. PubMed ID: 36195064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
    Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
    Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
    J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Nishiyama-Fujita Y; Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto K; Fujita H; Fujioka I; Tsuchiya S; Kimura Y; Iwanaga E; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
    Ann Med; 2022 Dec; 54(1):1244-1254. PubMed ID: 35486442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
    Basbous S; Levescot A; Piccirilli N; Brizard F; Guilhot F; Roy L; Bourmeyster N; Gombert JM; Herbelin A
    J Pathol; 2016 Nov; 240(3):262-268. PubMed ID: 27513300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
    McMullan RR; McConville C; McMullin MF
    Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
    Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
    J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients.
    Zahran AM; Badrawy H; Ibrahim A
    Int J Clin Oncol; 2014 Aug; 19(4):753-60. PubMed ID: 24068564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
    Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Rea D; Mahon FX
    Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells.
    Pearson S; Whetton AD; Pierce A
    PLoS One; 2022; 17(3):e0266298. PubMed ID: 35358275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
    Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
    Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.